Scienmag

SEPTEMBER 24, 2021

. — A new study delves into the evolution and function of the human growth hormone receptor gene, and asks what forces in humanity’s past may have driven changes to this vital piece of DNA. Genome assembly diagrams generated by the Integrative Genomics […].

Gene 52

Gene Scientist Genomics Genome 52

The Pharma Data

SEPTEMBER 6, 2021

Genomic data from the phase II CUPISCO study in Cancer of Unknown Primary (CUP), an uncommon type of cancer with high unmet need, could support diagnostics and more personalised treatment plans. Comprehensive genomic profiling. Comprehensive genomic profiling. Comprehensive genomic profiling. Real world data.

Genome 52

Genome Genomics HR Hormones 52

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40

Roots Analysis

SEPTEMBER 9, 2024

Protein expression is a potent technology in the field of synthetic biology, that is utilized for the high-throughput production of proteins as well as enzymes and oligonucleotides (DNA / RNA). This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

OCTOBER 14, 2020

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., AZP-3601 is a parathyroid hormone (PTH) analog that targets a specific configuration of the PTH receptor, thereby inducing a prolonged increase in blood calcium levels. The patent is valid through 2038. Ltd of Japan.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Alnylam discovers, develops and commercialises drugs based on RNAi interference.

Antibody 130

Antibody Hormones DNA Genome 130

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). Final results from this study were recently presented at the ESMO Virtual Congress 2020. Organon & Co.

Sales 40

Sales Vaccine Vaccination Production 40